#1 Clinical Trials Search in Europe

Methyl Aminolevulinate

Methyl Aminolevulinate, also known as MAL or Metvix, is a drug being studied in clinical trials for various skin conditions. It is primarily used in photodynamic therapy (PDT) to treat actinic keratosis, basal cell carcinoma, and photodamaged skin. This article summarizes key findings from recent clinical trials exploring the efficacy and safety of Methyl Aminolevulinate for these dermatological applications.

Table of Contents

What is Methyl Aminolevulinate?

Methyl Aminolevulinate, also known as MAL, is a medication used in a treatment called photodynamic therapy (PDT). It is marketed under the brand name Metvix[1]. This drug is primarily used to treat various skin conditions and is currently approved for use in several countries, including those in Europe and Australia[1].

Conditions Treated with Methyl Aminolevulinate

Methyl Aminolevulinate is used to treat several skin conditions, including:

  • Actinic Keratosis (AK): These are rough, scaly patches on the skin caused by years of sun exposure. They are considered precancerous lesions[2].
  • Basal Cell Carcinoma (BCC): This is a type of skin cancer that begins in the basal cells, which produce new skin cells[3].
  • Bowen’s Disease: This is an early form of skin cancer that affects the upper layer of skin[3].
  • Photoaged Skin: This refers to skin damage caused by prolonged exposure to sunlight or other ultraviolet light sources[1].
  • Acne Vulgaris: This is a common skin condition characterized by pimples, especially on the face, shoulders, and upper back[4].

In addition to these skin conditions, research is also being conducted on the use of Methyl Aminolevulinate for treating cervical dysplasia, which are precancerous changes in the cells of the cervix[5].

How Methyl Aminolevulinate Works

Methyl Aminolevulinate works through a process called photodynamic therapy (PDT). Here’s how it works:

  1. The medication is applied to the affected area of skin.
  2. The skin absorbs the medication, which accumulates in the abnormal cells.
  3. After a specific period, the treated area is exposed to a special red light.
  4. The light activates the medication, which then destroys the abnormal cells while largely sparing healthy tissue[2].

This targeted approach makes PDT with Methyl Aminolevulinate a selective, tissue-preserving method of treatment[5].

How Methyl Aminolevulinate is Administered

The administration of Methyl Aminolevulinate typically follows these steps:

  1. The affected area may undergo mild curettage (gentle scraping of the skin surface).
  2. A sunscreen is applied to protect surrounding skin.
  3. Methyl Aminolevulinate cream is applied to the treatment area.
  4. The area is covered and left for a specific period (usually 1.5 to 3 hours).
  5. The cream is removed, and the area is exposed to a specific type of red light for about 7-10 minutes[2][3].

In some cases, particularly for treating actinic keratosis, a variation called “daylight PDT” may be used. In this method, natural daylight is used instead of artificial red light[6].

Effectiveness of Methyl Aminolevulinate

Clinical trials have shown Methyl Aminolevulinate to be effective in treating various skin conditions:

  • For actinic keratosis, studies have shown significant reduction in lesions after treatment[2].
  • In treating photoaged skin, improvements have been observed in fine lines, skin roughness, and mottled pigmentation[1].
  • For acne, studies have shown reduction in inflammatory lesions[4].

The effectiveness can vary depending on the condition being treated, the specific protocol used, and individual patient factors.

Possible Side Effects and Tolerability

While Methyl Aminolevulinate is generally well-tolerated, some side effects may occur. These can include:

  • Erythema: Redness of the skin
  • Edema: Swelling
  • Scaling: Flaking of the skin
  • Crusting: Formation of scabs
  • Skin discomfort: Including pain or itching[1]

These effects are usually mild to moderate and typically resolve within a few days to weeks after treatment. The intensity of side effects can vary based on the treatment area, duration of application, and individual skin sensitivity[1][7].

Ongoing Research and Future Applications

Research into new applications for Methyl Aminolevulinate is ongoing. Some areas of current investigation include:

  • Treatment of cervical dysplasia, which could provide a tissue-preserving alternative to surgical methods[5].
  • Use in patients with darker skin types (IV-VI) for treating acne, as traditional PDT can sometimes cause pigmentation issues in these skin types[7].
  • Optimization of daylight PDT protocols for easier and more convenient treatment of actinic keratosis[6].

These ongoing studies aim to expand the use of Methyl Aminolevulinate and improve treatment protocols for various skin conditions.

Condition Treatment Key Findings
Actinic Keratosis MAL + Daylight PDT Effective in reducing AK lesions; well-tolerated by patients
Basal Cell Carcinoma MAL + Red Light PDT Studied for large/multiple superficial BCCs; results pending
Photodamaged Skin MAL + Red Light PDT Improved fine lines, pigmentation, and skin texture
Acne Vulgaris MAL + Red Light PDT Reduced inflammatory lesions; ongoing studies for optimal dosing
Facial Photodamage MAL + Daylight PDT Improved overall photodamage; patient satisfaction assessed

FAQ

  • What is Methyl Aminolevulinate used for in clinical trials? Methyl Aminolevulinate is being studied for treating actinic keratosis, basal cell carcinoma, Bowen's disease, photodamaged skin, and acne vulgaris using photodynamic therapy.
  • How is Methyl Aminolevulinate administered in these trials? It is typically applied as a cream to the affected skin area, left for 1.5-3 hours, then exposed to a specific wavelength of light to activate the drug.
  • What is daylight photodynamic therapy? Daylight PDT involves applying Methyl Aminolevulinate cream and then exposing the skin to natural daylight for about 2 hours, instead of using artificial light sources.
  • What are some potential side effects of Methyl Aminolevulinate PDT? Common side effects may include skin redness, swelling, scaling, crusting, and discomfort during and after treatment. Most side effects are temporary.
  • How effective is Methyl Aminolevulinate PDT for treating actinic keratosis? Clinical trials have shown it to be effective in reducing actinic keratosis lesions, with one study finding significant clinical improvement 3 months after treatment.

Ongoing Clinical Trials on Methyl Aminolevulinate

  • Study on the Use of Methyl Aminolevulinate and PAGETEX Device for Treating Vulvar Extra-Mammary Paget’s Disease in Women

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Actinic Keratosis: A rough, scaly patch on the skin caused by years of sun exposure. It's considered a precancerous growth.
  • Basal Cell Carcinoma: The most common type of skin cancer. It rarely spreads to other parts of the body.
  • Bowen's Disease: A very early form of skin cancer that's easily treatable. It appears as a persistent, scaly red patch on the skin.
  • Photodynamic Therapy (PDT): A treatment that uses special drugs, called photosensitizing agents, and light to kill cancer cells and abnormal skin cells.
  • Methyl Aminolevulinate (MAL): A drug used in photodynamic therapy. When applied to the skin and exposed to light, it helps destroy abnormal cells.
  • Photodamage: Skin damage caused by exposure to ultraviolet light from the sun or other sources.
  • Telangiectasia: Small dilated blood vessels near the surface of the skin, often referred to as spider veins.
  • Erythema: Redness of the skin caused by increased blood flow in superficial capillaries.
  • Hyperpigmentation: Darkening of areas of skin due to increased melanin production.
  • Hypopigmentation: Lightening of areas of skin due to decreased melanin production.

References

  1. https://clinicaltrials.gov/study/NCT00437320
  2. https://clinicaltrials.gov/study/NCT03013647
  3. https://clinicaltrials.gov/study/NCT00535080
  4. https://clinicaltrials.gov/study/NCT00594425
  5. https://clinicaltrials.gov/study/NCT00369018
  6. https://clinicaltrials.gov/study/NCT03511326
  7. https://clinicaltrials.gov/study/NCT00673933